{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:06:04Z","timestamp":1780668364257,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijid.2025.108145","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T16:01:19Z","timestamp":1760803279000},"page":"108145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Minimal impact of pregnancy on rilpivirine pharmacokinetics in women living with HIV"],"prefix":"10.1016","volume":"161","author":[{"given":"Benjamin","family":"Kably","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Tubiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Le Hingrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Wirden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelie","family":"Julia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naima","family":"Hamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mandelbrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-8288","authenticated-orcid":false,"given":"Minh P","family":"L\u00ea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.108145_bib0001","series-title":"USA. Panel on treatment of HIV during pregnancy and prevention of perinatal transmission","year":"2024"},{"key":"10.1016\/j.ijid.2025.108145_bib0002","series-title":"EACS Guidelines","year":"2024"},{"key":"10.1016\/j.ijid.2025.108145_bib0003","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/QAI.0000000000000968","article-title":"Pharmacokinetics of rilpivirine in HIV-infected pregnant women","volume":"72","author":"Tran","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2025.108145_bib0004","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/cid\/cix534","article-title":"Lowered rilpivirine exposure during the third trimester of pregnancy in human immunodeficiency virus Type 1\u2013infected women","volume":"65","author":"Schalkwijk","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108145_bib0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40121-017-0184-8","article-title":"Pharmacokinetics, antiviral activity, and safety of rilpivirine in pregnant women with HIV-1 infection: results of a phase 3b, multicenter, open-label study","volume":"7","author":"Osiyemi","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijid.2025.108145_bib0006","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.ijid.2025.108145_bib0007","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00228-017-2405-1","article-title":"Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine\/tenofovir\/emtricitabine","volume":"74","author":"N\u00e9ant","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2025.108145_bib0008","series-title":"Generalized additive modeling of virologic response to the non-nucleoside reverse transcriptase inhibitors rilpivirine and efavirenz in treatment-na\u00efve HIV-infected patients: pooled data from ECHO and THRIVE","author":"Brochot","year":"2011"},{"key":"10.1016\/j.ijid.2025.108145_bib0009","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/AAC.00986-09","article-title":"TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1","volume":"54","author":"Azijn","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2025.108145_bib0010","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/QAI.0000000000001677","article-title":"Rilpivirine plasma and cervicovaginal concentrations in women during pregnancy and postpartum","volume":"78","author":"Eke","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2025.108145_bib0011","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAD.0000000000003616","article-title":"Modern antiretroviral regimens in pregnant women: virologic outcomes and durability","volume":"38","author":"Smith","year":"2024","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2025.108145_bib0012","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/jac\/dkx275","article-title":"Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals","volume":"72","author":"L\u00ea","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2025.108145_bib0013","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1128\/AAC.00075-15","article-title":"Placental transfer of rilpivirine in an ex vivo human cotyledon perfusion model","volume":"59","author":"Mandelbrot","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2025.108145_bib0014","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/QAD.0000000000003955","article-title":"First-trimester exposure to newer antiretroviral agents and congenital anomalies in a US cohort","volume":"38","author":"Fung","year":"2024","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2025.108145_bib0015","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/cid\/ciae242","article-title":"Long-acting injectable cabotegravir and rilpivirine in a pregnant woman with HIV","volume":"79","author":"Van Der Wekken-Pas","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108145_bib0016","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bcp.16006","article-title":"Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy","volume":"91","author":"Atoyebi","year":"2025","journal-title":"Br J Clin Pharmacol"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225003674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225003674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:06:56Z","timestamp":1780664816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225003674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":16,"alternative-id":["S1201971225003674"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108145","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal impact of pregnancy on rilpivirine pharmacokinetics in women living with HIV","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108145"}}